BioNTech Sell-Off From Co-Founder Exits Seen as Overblown -- Market Talk

Dow Jones03-11

1517 ET - BioNTech shares fall 18% after married co-founders Ugur Sahin and Özlem Türeci, chief executive and chief medical officer respectively, announce their departure to form a startup. But Evercore ISI analysts see the market reaction as overblown, adding that the current price may be a good opportunity to buy. "This biotech power couple unequivocally built BNTX into what it is today, but this is also the right time for a transition," the analysts write. "There is a clear need for a more commercially focused C-suite. These seats should be highly coveted. Fill them with the right people & investors may look back on this day as a golden opportunity." (elias.schisgall@wsj.com)

(END) Dow Jones Newswires

March 10, 2026 15:17 ET (19:17 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment